Biogen said more data had become available after the two aducanumab studies were discontinued, resulting in a new analysis that showed one of the trials met the main goal. Photograph: Reuters

Biogen revived plans on Tuesday to seek US approval for Alzheimer’s treatment aducanumab, surprising investors and saying data from more patients in t(...)

A long-awaited drug treatment which can halt Alzheimer’s disease may be on the horizon after promising results from an early-stage clinical trial. File photograph: Peter Byrne/PA Wire

A long-awaited drug treatment which can halt Alzheimer’s disease may be on the horizon after promising results from an early-stage clinical trial. Ex(...)